{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:08:19Z","timestamp":1783822099777,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01563-x","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:14:55Z","timestamp":1780060495000},"page":"809-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Micronized Purified Flavonoid Fraction on Quality of Life in Patients with Chronic Venous Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-8989","authenticated-orcid":false,"given":"Fabricio Rodrigues","family":"Santiago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-9397","authenticated-orcid":false,"given":"Denisa","family":"Celovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-6264","authenticated-orcid":false,"given":"Sarah","family":"Thomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-178X","authenticated-orcid":false,"given":"Vanessa","family":"Blanc-Guillemaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-1369","authenticated-orcid":false,"given":"Marie-Blanche","family":"Onselaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumeya","family":"Serifou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hurrem-Pelin","family":"Yaltirik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1302","authenticated-orcid":false,"given":"Mamuka","family":"Bokuchava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"6","key":"1563_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/sla.0000000000004631","volume":"274","author":"S Salim","year":"2021","unstructured":"Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971\u20136. https:\/\/doi.org\/10.1097\/sla.0000000000004631.","journal-title":"Ann Surg"},{"issue":"9","key":"1563_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/0003319718759834","volume":"69","author":"ME Vuylsteke","year":"2018","unstructured":"Vuylsteke ME, Colman R, Thomis S, Guillaume G, Van Quickenborne D, Staelens I. An epidemiological survey of venous disease among general practitioner attendees in different geographical regions on the globe: the final results of the Vein Consult Program. Angiology. 2018;69(9):779\u201385. https:\/\/doi.org\/10.1177\/0003319718759834.","journal-title":"Angiology"},{"issue":"1","key":"1563_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jvsv.2014.09.008","volume":"3","author":"AJ Lee","year":"2015","unstructured":"Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18\u201326. https:\/\/doi.org\/10.1016\/j.jvsv.2014.09.008.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"Suppl 1","key":"1563_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-019-0882-6","volume":"36","author":"AN Nicolaides","year":"2019","unstructured":"Nicolaides AN, Labropoulos N. Burden and suffering in chronic venous disease. Adv Ther. 2019;36(Suppl 1):1\u20134. https:\/\/doi.org\/10.1007\/s12325-019-0882-6.","journal-title":"Adv Ther"},{"issue":"1 Suppl","key":"1563_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0268355516628359","volume":"31","author":"S Onida","year":"2016","unstructured":"Onida S, Davies AH. Predicted burden of venous disease. Phlebology. 2016;31(1 Suppl):74\u20139. https:\/\/doi.org\/10.1177\/0268355516628359.","journal-title":"Phlebology"},{"issue":"3","key":"1563_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.23736\/s0392-9590.18.03999-8","volume":"37","author":"A Nicolaides","year":"2018","unstructured":"Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181\u2013254. https:\/\/doi.org\/10.23736\/s0392-9590.18.03999-8.","journal-title":"Int Angiol"},{"issue":"17","key":"1563_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2217\/cer-2020-0158","volume":"9","author":"E Rabe","year":"2020","unstructured":"Rabe E, Regnier C, Goron F, Salmat G, Pannier F. The prevalence, disease characteristics and treatment of chronic venous disease: an international web-based survey. J Comp Eff Res. 2020;9(17):1205\u201318. https:\/\/doi.org\/10.2217\/cer-2020-0158.","journal-title":"J Comp Eff Res"},{"issue":"Suppl 1","key":"1563_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12325-019-0881-7","volume":"36","author":"AH Davies","year":"2019","unstructured":"Davies AH. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther. 2019;36(Suppl 1):5\u201312. https:\/\/doi.org\/10.1007\/s12325-019-0881-7.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1563_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12325-019-01217-9","volume":"37","author":"A Mansilha","year":"2020","unstructured":"Mansilha A. Early stages of chronic venous disease: medical treatment alone or in addition to endovenous treatments. Adv Ther. 2020;37(Suppl 1):13\u20138. https:\/\/doi.org\/10.1007\/s12325-019-01217-9.","journal-title":"Adv Ther"},{"issue":"4","key":"1563_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jvn.2021.07.007","volume":"39","author":"H Kiloatar","year":"2021","unstructured":"Kiloatar H, Aras O, Korkmaz M, Vural AH. An evaluation of quality of life, physical activity level and symptoms in patients with early stages of chronic venous disease. J Vasc Nurs. 2021;39(4):108\u201313. https:\/\/doi.org\/10.1016\/j.jvn.2021.07.007.","journal-title":"J Vasc Nurs"},{"issue":"Suppl 1","key":"1563_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12325-019-0884-4","volume":"36","author":"JH Ulloa","year":"2019","unstructured":"Ulloa JH. Micronized purified flavonoid fraction (MPFF) for patients suffering from chronic venous disease: a review of new evidence. Adv Ther. 2019;36(Suppl 1):20\u20135. https:\/\/doi.org\/10.1007\/s12325-019-0884-4.","journal-title":"Adv Ther"},{"issue":"4","key":"1563_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejvs.2012.01.008","volume":"43","author":"K Sritharan","year":"2012","unstructured":"Sritharan K, Lane TR, Davies AH. The burden of depression in patients with symptomatic varicose veins. Eur J Vasc Endovasc Surg. 2012;43(4):480\u20134. https:\/\/doi.org\/10.1016\/j.ejvs.2012.01.008.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"40","key":"1563_CR13","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1093\/eurheartj\/ehab495","volume":"42","author":"JH Prochaska","year":"2021","unstructured":"Prochaska JH, Arnold N, Falcke A, Kopp S, Schulz A, Buch G, et al. Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. Eur Heart J. 2021;42(40):4157\u201365. https:\/\/doi.org\/10.1093\/eurheartj\/ehab495.","journal-title":"Eur Heart J"},{"issue":"6","key":"1563_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034245","volume":"10","author":"NC Wu","year":"2020","unstructured":"Wu NC, Chen ZC, Feng IJ, Ho CH, Chiang CY, Wang JJ, et al. Severe varicose veins and the risk of mortality: a nationwide population-based cohort study. BMJ Open. 2020;10(6):e034245. https:\/\/doi.org\/10.1136\/bmjopen-2019-034245.","journal-title":"BMJ Open"},{"issue":"3","key":"1563_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jvsv.2021.08.021","volume":"10","author":"TP Singh","year":"2022","unstructured":"Singh TP, Velu RB, Quigley F, Golledge J. Association of chronic venous disease with major adverse cardiovascular events. J Vasc Surg Venous Lymphat Disord. 2022;10(3):683\u20138. https:\/\/doi.org\/10.1016\/j.jvsv.2021.08.021.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"2","key":"1563_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jvsv.2014.08.005","volume":"3","author":"R Launois","year":"2015","unstructured":"Launois R. Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. J Vasc Surg Venous Lymphat Disord. 2015;3(2):219-27 e1-3. https:\/\/doi.org\/10.1016\/j.jvsv.2014.08.005.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"6","key":"1563_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.23736\/s0392-9590.23.05108-8","volume":"42","author":"JH Ulloa","year":"2023","unstructured":"Ulloa JH, Lurie F, Santiago FR, Gianesini S, Reina L, Wang J, et al. Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease. Int Angiol. 2023;42(6):465\u201376. https:\/\/doi.org\/10.23736\/s0392-9590.23.05108-8.","journal-title":"Int Angiol"},{"issue":"10","key":"1563_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0268355513501302","volume":"29","author":"ML Kuet","year":"2014","unstructured":"Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648\u201353. https:\/\/doi.org\/10.1177\/0268355513501302.","journal-title":"Phlebology"},{"issue":"20","key":"1563_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000025921","volume":"100","author":"Z Wu","year":"2021","unstructured":"Wu Z, Ma Y. A narrative review of the quality of life scales specific for chronic venous diseases. Medicine (Baltimore). 2021;100(20):e25921. https:\/\/doi.org\/10.1097\/md.0000000000025921.","journal-title":"Medicine (Baltimore)"},{"key":"1563_CR20","doi-asserted-by":"publisher","DOI":"10.1590\/1677-5449.202102292","volume":"21","author":"I de Almeida","year":"2022","unstructured":"de Almeida I, Figueiredo PHS, Silva WT, Mendonca VA, Lacerda ACR, Lima VP, et al. Reliability and validity of specific quality of life assessment questionnaires related to chronic venous insufficiency: a systematic review. J Vasc Bras. 2022;21:e20210229. https:\/\/doi.org\/10.1590\/1677-5449.202102292.","journal-title":"J Vasc Bras"},{"issue":"3","key":"1563_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jvsv.2014.09.003","volume":"3","author":"FS Catarinella","year":"2015","unstructured":"Catarinella FS, Nieman FH, Wittens CH. An overview of the most commonly used venous quality of life and clinical outcome measurements. J Vasc Surg Venous Lymphat Disord. 2015;3(3):333\u201340. https:\/\/doi.org\/10.1016\/j.jvsv.2014.09.003.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"6","key":"1563_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s11136-011-0008-3","volume":"21","author":"R Launois","year":"2012","unstructured":"Launois R, Le Moine JG, Lozano FS, Mansilha A. Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure. Qual Life Res. 2012;21(6):1051\u20138. https:\/\/doi.org\/10.1007\/s11136-011-0008-3.","journal-title":"Qual Life Res"},{"issue":"2","key":"1563_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3892\/etm.2018.7054","volume":"17","author":"DE Branisteanu","year":"2019","unstructured":"Branisteanu DE, Feodor T, Baila S, Mitea IA, Vittos O. Impact of chronic venous disease on quality of life: results of vein alarm study. Exp Ther Med. 2019;17(2):1091\u20136. https:\/\/doi.org\/10.3892\/etm.2018.7054.","journal-title":"Exp Ther Med"},{"issue":"4","key":"1563_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jvs.2003.12.007","volume":"39","author":"SR Kahn","year":"2004","unstructured":"Kahn SR, M\u2019Lan CE, Lamping DL, Kurz X, Berard A, Abenhaim LA. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: Results from an international cohort study. J Vasc Surg. 2004;39(4):823\u20138. https:\/\/doi.org\/10.1016\/j.jvs.2003.12.007.","journal-title":"J Vasc Surg"},{"issue":"5","key":"1563_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1067\/mva.2003.168","volume":"37","author":"RM Kaplan","year":"2003","unstructured":"Kaplan RM, Criqui MH, Denenberg JO, Bergan J, Fronek A. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg. 2003;37(5):1047\u201353. https:\/\/doi.org\/10.1067\/mva.2003.168.","journal-title":"J Vasc Surg"},{"issue":"8","key":"1563_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/bjs.7500","volume":"98","author":"D Carradice","year":"2011","unstructured":"Carradice D, Mazari FA, Samuel N, Allgar V, Hatfield J, Chetter IC. Modelling the effect of venous disease on quality of life. Br J Surg. 2011;98(8):1089\u201398. https:\/\/doi.org\/10.1002\/bjs.7500.","journal-title":"Br J Surg"},{"issue":"6","key":"1563_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1258\/phleb.2008.008067","volume":"23","author":"JJ Guex","year":"2008","unstructured":"Guex JJ. Patient-reported outcome or physician-reported outcome? Phlebology. 2008;23(6):251. https:\/\/doi.org\/10.1258\/phleb.2008.008067.","journal-title":"Phlebology"},{"issue":"7","key":"1563_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s12325-018-0731-z","volume":"35","author":"VY Bogachev","year":"2018","unstructured":"Bogachev VY, Boldin BV, Turkin PY. Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: Results of the national, multicenter, observational program VEIN ACT PROLONGED-C1. Adv Ther. 2018;35(7):1001\u20138. https:\/\/doi.org\/10.1007\/s12325-018-0731-z.","journal-title":"Adv Ther"},{"issue":"2","key":"1563_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.23736\/s0392-9590.18.03975-5","volume":"37","author":"SK Kakkos","year":"2018","unstructured":"Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143\u201354. https:\/\/doi.org\/10.23736\/s0392-9590.18.03975-5.","journal-title":"Int Angiol"},{"issue":"9","key":"1563_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139. https:\/\/doi.org\/10.1016\/j.rec.2021.07.010.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"1563_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"1563_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1563_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1563_CR34","unstructured":"Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for systematic reviews of interventions version 6.5. Chapter 6."},{"issue":"3","key":"1563_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12325-020-01232-1","volume":"37","author":"AA Bignamini","year":"2020","unstructured":"Bignamini AA, Matuska J. Sulodexide for the symptoms and signs of chronic venous disease: A systematic review and meta-analysis. Adv Ther. 2020;37(3):1013\u201333. https:\/\/doi.org\/10.1007\/s12325-020-01232-1.","journal-title":"Adv Ther"},{"issue":"11","key":"1563_CR36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"7414","key":"1563_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"3","key":"1563_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"issue":"7","key":"1563_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/0268355513489550","volume":"29","author":"SQ Belczak","year":"2014","unstructured":"Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R. Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014;29(7):454\u201360. https:\/\/doi.org\/10.1177\/0268355513489550.","journal-title":"Phlebology"},{"issue":"10","key":"1563_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/fca-2022-0026","volume":"18","author":"V Bogachev","year":"2022","unstructured":"Bogachev V, Boldin B, Turkin P, Samenkov A, Dzhenina O. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting. Future Cardiol. 2022;18(10):777\u201385. https:\/\/doi.org\/10.2217\/fca-2022-0026.","journal-title":"Future Cardiol"},{"issue":"5","key":"1563_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.23736\/s0392-9590.17.03801-9","volume":"36","author":"P Carpentier","year":"2017","unstructured":"Carpentier P, van Bellen B, Karetova D, Hanafiah H, Enriquez-Vega E, Kirienko A, et al. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial. Int Angiol. 2017;36(5):402\u20139. https:\/\/doi.org\/10.23736\/s0392-9590.17.03801-9.","journal-title":"Int Angiol"},{"issue":"3","key":"1563_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/000331970205300301","volume":"53","author":"G Jantet","year":"2002","unstructured":"Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized flavonoids. Angiology. 2002;53(3):245\u201356. https:\/\/doi.org\/10.1177\/000331970205300301.","journal-title":"Angiology"},{"issue":"6","key":"1563_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.23736\/s0392-9590.22.04987-2","volume":"41","author":"A Mansilha","year":"2022","unstructured":"Mansilha A, Caldevilla H, Puskas A, Lucien A, Roby L, Kirienko A. MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial. Int Angiol. 2022;41(6):464\u201375. https:\/\/doi.org\/10.23736\/s0392-9590.22.04987-2.","journal-title":"Int Angiol"},{"issue":"5","key":"1563_CR44","first-page":"428","volume":"34","author":"E Rabe","year":"2015","unstructured":"Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428\u201336.","journal-title":"Int Angiol"},{"key":"1563_CR45","first-page":"18","volume":"22","author":"YT Tsoukanov","year":"2015","unstructured":"Tsoukanov YT, Tsoukanov AY, Nikolaychuk AI. Great sphenous vein transitory reflux in patients with symptoms related to chronic venous disorders, but without visible signs (C0s), and its correction with MPFF treatment. Phlebolymphology. 2015;22:18\u201324.","journal-title":"Phlebolymphology."},{"issue":"2","key":"1563_CR46","first-page":"110","volume":"22","author":"YT Tsukanov","year":"2016","unstructured":"Tsukanov YT, Nikolaichuk AI. [Transitory (evening) venous reflux in patients with intracutaneous varicosity and medicamentous correction thereof]. Angiol Sosud Khir. 2016;22(2):110\u20136 (written Tsukanov and Nikolaichuk (A) in the manuscript).","journal-title":"Angiol Sosud Khir"},{"issue":"2","key":"1563_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.23736\/s0392-9590.16.03708-1","volume":"36","author":"YT Tsukanov","year":"2017","unstructured":"Tsukanov YT, Nikolaichuk AI. Orthostatic-loading-induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein. Int Angiol. 2017;36(2):189\u201396. https:\/\/doi.org\/10.23736\/s0392-9590.16.03708-1. (written Tsukanov and Nikolaichuk (B) in the manuscript).","journal-title":"Int Angiol"},{"issue":"3","key":"1563_CR48","first-page":"144","volume":"24","author":"YT Tsukanov","year":"2017","unstructured":"Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational Great Saphenous Vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144\u201351.","journal-title":"Phlebolymphology"},{"issue":"2","key":"1563_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/000331970605700201","volume":"57","author":"MR Cesarone","year":"2006","unstructured":"Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology. 2006;57(2):131\u20138. https:\/\/doi.org\/10.1177\/000331970605700201.","journal-title":"Angiology"},{"key":"1563_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jclinepi.2017.11.025","volume":"95","author":"KM Rhodes","year":"2018","unstructured":"Rhodes KM, Turner RM, Savovic J, Jones HE, Mawdsley D, Higgins JPT. Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics. J Clin Epidemiol. 2018;95:45\u201354. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.11.025.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"1563_CR51","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1007\/s12325-023-02643-6","volume":"40","author":"ZT Mezalek","year":"2023","unstructured":"Mezalek ZT, Feodor T, Chernukha L, Chen Z, Rueda A, Sanchez IE, et al. VEIN STEP: a prospective, observational, international study to assess effectiveness of conservative treatments in chronic venous disease. Adv Ther. 2023;40(11):5016\u201336. https:\/\/doi.org\/10.1007\/s12325-023-02643-6.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1563_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40261-023-01264-9","volume":"43","author":"F Santiago","year":"2023","unstructured":"Santiago F. Quality of life in chronic venous disease: bridging the gap between patients and physicians. Clin Drug Investig. 2023;43(Suppl 1):3\u20138. https:\/\/doi.org\/10.1007\/s40261-023-01264-9.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1563_CR53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1067\/mva.2001.117333","volume":"34","author":"X Kurz","year":"2001","unstructured":"Kurz X, Lamping DL, Kahn SR, Baccaglini U, Zuccarelli F, Spreafico G, et al. Do varicose veins affect quality of life? Results of an international population-based study. J Vasc Surg. 2001;34(4):641\u20138. https:\/\/doi.org\/10.1067\/mva.2001.117333.","journal-title":"J Vasc Surg"},{"issue":"3","key":"1563_CR54","first-page":"272","volume":"24","author":"GM Andreozzi","year":"2005","unstructured":"Andreozzi GM, Cordova RM, Scomparin A, Martini R, D\u2019Eri A, Andreozzi F. Quality of life in chronic venous insufficiency. An Italian pilot study of the Triveneto Region. Int Angiol. 2005;24(3):272\u20137.","journal-title":"Int Angiol"},{"issue":"1","key":"1563_CR55","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5606\/tgkdc.dergisi.2020.18068","volume":"28","author":"I Keser","year":"2020","unstructured":"Keser I, Ozdemir K, Erer D, Onurlu I, Bezgin S. Differences in pain, fatigue, and quality of life in patients with chronic venous insufficiency based on physical activity level. Turk Gogus Kalp Damar Cerrahisi Derg. 2020;28(1):76\u201383. https:\/\/doi.org\/10.5606\/tgkdc.dergisi.2020.18068.","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"issue":"11","key":"1563_CR56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48093","volume":"15","author":"A Singh","year":"2023","unstructured":"Singh A, Gattani R. A narrative review of advancements in understanding and treating varicose veins. Cureus. 2023;15(11):e48093. https:\/\/doi.org\/10.7759\/cureus.48093.","journal-title":"Cureus"},{"key":"1563_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003229.pub4","author":"MJ Martinez-Zapata","year":"2020","unstructured":"Martinez-Zapata MJ, Vernooij RWM, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.cd003229.pub4.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01563-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:12Z","timestamp":1783821732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01563-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01563-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Denisa CELOVSKA has received honoraria for lectures from Alfasigma, Amgen, Bayer, Boehringer-Ingelheim, Elly-Lilly, Novartis, Pfizer, and Servier. Sarah THOMIS, Mamuka BOKUCHAVA, and Fabricio Rodrigues SANTIAGO have no conflicts of interest to declare. Vanessa BLANC-GUILLEMAUD and Hurrem-Pelin YALTIRIK are employees of Servier, France. Marie-Blanche ONSELAER is an employee of Soladis Clinical Studies that received fees from Servier Medical Affairs to conduct this work. Soumeya SERIFOU is an employee of Soladis that received fees from Servier Medical Affairs to conduct this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data supporting study findings are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Ethics approvals were not required for this systematic review, as it did not involve human participants or animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Concept and design (all authors), data acquisition (Vanessa BLANC-GUILLEMAUD and Marie-Blanche ONSELAER), statistical analysis (Soumeya SERIFOU), interpretation of data for the work (all authors), drafting the manuscript (Marie-Blanche ONSELAER, Vanessa BLANC-GUILLEMAUD and Hurrem-Pelin YALTIRIK), review of manuscript (all authors), and final approval (all authors). All authors read and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}